Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | MRNA | Common Stock | Options Exercise | $0 | +703 | +0.03% | $0.00 | 2.24M | Apr 28, 2022 | Direct | F1 |
holding | MRNA | Common Stock | 3.92K | Apr 28, 2022 | By: Flagship Pioneering, Inc. | F2 | |||||
holding | MRNA | Common Stock | 11.5M | Apr 28, 2022 | By: Flagship Venture Labs IV LLC | F3 | |||||
holding | MRNA | Common Stock | 3.28M | Apr 28, 2022 | By: Flagship Ventures Fund IV, LP | F4 | |||||
holding | MRNA | Common Stock | 2.84M | Apr 28, 2022 | By: Flagship Ventures Fund IV-Rx, LP | F5 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | MRNA | Stock Option (Right to Buy) | Award | $0 | +5.42K | $0.00 | 5.42K | Apr 28, 2022 | Common Stock | 5.42K | $142.52 | Direct | F6 | |
transaction | MRNA | Restricted Stock Units | Options Exercise | $0 | -703 | -100% | $0.00* | 0 | Apr 28, 2022 | Common Stock | 703 | $0.00 | Direct | F1, F7 |
Id | Content |
---|---|
F1 | Restricted stock units convert into common stock on a one-for-one basis. |
F2 | Securities held by Flagship Pioneering, Inc. ("Flagship Pioneering"). Noubar B. Afeyan, Ph.D. is the CEO and a stockholder of Flagship Pioneering. Each of the reporting persons except for Flagship Pioneering disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
F3 | Shares held by Flagship VentureLabs IV LLC ("VentureLabs IV"). Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") is a member of VentureLabs IV and also serves as its manager. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole the manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
F4 | Shares held by Flagship Ventures Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
F5 | Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
F6 | This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. |
F7 | The shares subject to this restricted stock unit award vested in full on April 28, 2022. |